Notice of Proposed Sale · 144
Invivyd, Inc.
IVVDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Invivyd, Inc.
- Issuer CIK
- 0001832038
- SEC file number
- 001-40703
- Phone
- 781-819-0080
- Person for whose account securities are to be sold
- Andersen Jill
- Relationships to issuer
- Officer
- Street
- 205 Church Street
- City
- New Haven
- State / country code
- CT
- Postal code
- 06510
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 68,001 | 49,021.92 | 294,758,746 | 08/17/2026 | Nasdaq | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 08/15/2026 | Common Stock acquired upon vesting of restricted stock units granted under the Issuer's 2021 Equity Incentive Plan | Issuer | 170,000 | N | 08/15/2026 | Equity Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
This Form 144 reports shares to be sold to satisfy the Reporting Person's tax obligations upon vesting of a restricted stock unit award in non-discretionary "sell-to-cover" transactions pursuant to a Rule 10b5-1 plan applicable to the Reporting Person. Aggregate Market Value of the sale is based on a closing price of $0.7209 for the Issuer's common stock on August 14, 2026. The actual number of shares sold will depend on the sale price of the Issuer's common stock at the time of sale.
Notice signature
- Notice date
- 08/17/2026
- Signed
- /s/ Jill Andersen
- Plan adoption dates
- 02/20/2025
Company context
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.